A KAUST scientist led a global call for climate solutions, published simultaneously by 14 academic journals and released at COP29. The publication, prepared by 18 scientists, urges international governments to deploy microbial 'vaccines' against climate change. Six simple 'vaccine' examples are outlined, including carbon sequestration boosters and methane busters. Why it matters: This coordinated effort highlights the urgency of addressing climate change and KAUST's leading role in microbial solutions.
The Saudi Vaccine and Biomanufacturing Center (SVBC), the first of its kind in the Middle East, broke ground at KAUST on December 15. The center will develop vaccines and biopharmaceutical products under good manufacturing practice (GMP) standards. It is a joint project championed by the Ministry of Energy, Industry and Mineral Resources through the Industrial Clusters Program and supported by KACST. Why it matters: The center will serve as a national platform for pharmaceutical innovation and address epidemic risks in the Kingdom, such as MERS-CoV.
KAUST Professor Raquel Peixoto will co-lead the first global body under the International Union for Conservation of Nature (IUCN) to safeguard microbial biodiversity. The Microbial Conservation Specialist Group will explore ecological disruption and potential extinction of microbes vital to ecosystems and human health. The group will assess extinction risks, set conservation priorities, and establish criteria for a microorganism Red List. Why it matters: This initiative highlights the growing recognition of the importance of microbial ecosystems and positions KAUST as a leader in integrating microbiology into global biodiversity governance.
The Research Products Development Company (RPDC) signed an agreement with The Saudi Vaccine and Biomanufacturing Center (SVBC) to establish a research and industrial center in Saudi Arabia for vaccine and biopharmaceutical development. Supported by KACST and hosted by KAUST, the SVBC will provide a state-of-the-art facility and a training platform. Cooperation agreements were also signed with GE for equipment supply and with Fujifilm Dayosent Biotechnology for MERS-CoV treatment development. Why it matters: This initiative aims to localize vaccine and advanced treatment industries in Saudi Arabia, create technical jobs, and reduce reliance on imports in line with Vision 2030.
SaudiVax, located in the KAUST Research & Technology Park, is collaborating with the University of Pittsburgh and Merck France to develop a COVID-19 antibody injection. The antibody both protects against potential infection and neutralizes the virus in those already infected. SaudiVax is utilizing KAUST expertise and has contracted with Merck France for manufacturing since suitable facilities are not yet available in Saudi Arabia. Why it matters: This partnership highlights the growing biopharmaceutical capabilities in Saudi Arabia and the potential for KAUST to serve as a hub for medical innovation in the region.
Professor Alexandre Rosado at King Abdullah University of Science and Technology (KAUST) conducts research on extremophile microbes, connecting Saudi Arabia’s unique extreme environments to space science and biotechnology. His interdisciplinary work focuses on microbial diversity, microbiome-based technologies, and extremophiles. Rosado collaborates with global space agencies and previously worked on bioremediation, including cleaning up a diesel spill in Antarctica. Why it matters: This research leverages Saudi Arabia's unique biodiversity for scientific discovery with potential applications in biotechnology and space exploration, though it is not directly related to artificial intelligence.